Education
About Us
Working with TipRanks
Follow Us
Bicara Therapeutics Inc. (BCAX)
NASDAQ:BCAX
BCAX Stock Chart & Stats
$18.20
-$0.31(-1.97%)
At close: 4:00 PM EST
$18.20
-$0.31(-1.97%)
Day’s Range― - ―
52-Week Range$7.80 - $22.68
Previous CloseN/A
Volume80.52K
Average Volume (3M)631.51K
Market Cap
$997.03M
Enterprise Value$573.37M
Total Cash (Recent Filing)$290.17M
Total Debt (Recent Filing)$1.98M
Price to Earnings (P/E)―
Beta1.46
Next Earnings
Mar 26, 2026EPS Estimate
-0.69Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.67
Shares Outstanding54,781,950
10 Day Avg. Volume624,253
30 Day Avg. Volume631,508
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)1.93
Price to Sales (P/S)0.00
P/FCF Ratio-12.67
Enterprise Value/Market Cap0.58
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-4.20
Forecast
1Y Price Target
$33.00Price Target Upside81.32% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical Trial PerformanceThe survival rates for patients treated with Ficerafusp Alfa and Keytruda are notably longer than those seen with current treatments, indicating a promising outlook.
Market PotentialRecent development and strategic updates across the HNSCC landscape, along with ficera's recent Breakthrough Therapy Designation, reinforce the view of the potential commercial opportunity in HNSCC and validation of BCAX's focus on HPV-negative patients.
Regulatory MilestonesThe FDA has granted Ficerafusp Alfa Breakthrough Therapy Designation for the treatment of certain types of head and neck cancer, highlighting its potential effectiveness.
Bears Say
Competitive PressureRybrevant demonstrated promising monotherapy activity in 2L+ R/M HNSCC, which is better compared to the limited monotherapy efficacy of Bicara’s FICERA in solid tumors.
Dose Efficacy ConcernsA key concern with the lower dose cohort has been reduced efficacy, as seen in Merus' previous studies with a similar drug.
Treatment SafetyOne grade 5 treatment-related adverse event was reported as acute respiratory distress syndrome, but it was deemed related to pembro.
Bicara Therapeutics Inc. News
BCAX FAQ
What was Bicara Therapeutics Inc.’s price range in the past 12 months?
Bicara Therapeutics Inc. lowest stock price was $7.80 and its highest was $22.68 in the past 12 months.
What is Bicara Therapeutics Inc.’s market cap?
Bicara Therapeutics Inc.’s market cap is $997.03M.
When is Bicara Therapeutics Inc.’s upcoming earnings report date?
Bicara Therapeutics Inc.’s upcoming earnings report date is Mar 26, 2026 which is in 109 days.
How were Bicara Therapeutics Inc.’s earnings last quarter?
Bicara Therapeutics Inc. released its earnings results on Nov 18, 2025. The company reported -$0.67 earnings per share for the quarter, missing the consensus estimate of -$0.541 by -$0.129.
Is Bicara Therapeutics Inc. overvalued?
According to Wall Street analysts Bicara Therapeutics Inc.’s price is currently Undervalued.
Does Bicara Therapeutics Inc. pay dividends?
Bicara Therapeutics Inc. does not currently pay dividends.
What is Bicara Therapeutics Inc.’s EPS estimate?
Bicara Therapeutics Inc.’s EPS estimate is -0.69.
How many shares outstanding does Bicara Therapeutics Inc. have?
Bicara Therapeutics Inc. has 54,781,950 shares outstanding.
What happened to Bicara Therapeutics Inc.’s price movement after its last earnings report?
Bicara Therapeutics Inc. reported an EPS of -$0.67 in its last earnings report, missing expectations of -$0.541. Following the earnings report the stock price went up 3.455%.
Which hedge fund is a major shareholder of Bicara Therapeutics Inc.?
Currently, no hedge funds are holding shares in BCAX
Bicara Therapeutics Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (81.32% Upside)
$33.00 (81.32% Upside)
Blogger Sentiment
Bullish
BCAX Sentiment 100%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 9.0%
Last 30 Days ▼ 9.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-6.85%
12-Months-Change
Fundamentals
Return on Equity
-26.64%
Trailing 12-Months
Asset Growth
-18.98%
Trailing 12-Months
Company Description
Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts. Bicara Therapeutics Inc. is a subsidiary of Biocon Limited.
BCAX Stock 12 Month Forecast
Average Price Target
$33.00
▲(81.32% Upside)
Technical Analysis
Arbutus Biopharma
―
Bicycle Therapeutics
―
Relay Therapeutics
―
Zenas BioPharma, Inc.
―
Upstream Bio, Inc.
―
Ownership Overview
17.57% Insiders
9.54% Mutual Funds
52.28% Other Institutional Investors
13.99% Public Companies and
Individual Investors